Lecanemab

Lecanemab: a review

Lecanemab: drawbacks to consider

Lecanemab vs aducanumab

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

Highlights from CTAD 2022

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

Future direction for anti-amyloid immunotherapies

Lecanemab and what this means for the future treatment of Alzheimer’s disease

The Phase III NILEAD trial: nilotinib as a novel treatment for AD

Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab

Important developments in dementia: biomarkers & clinical trials

Targeting β-amyloid and tau in Alzheimer’s disease

Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab

Lecanemab path to approval

The development of lecanemab & rationale behind its unique binding profile

The potential of lecanemab for the treatment of early Alzheimer’s disease